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We thank Dr Moore and colleagues for their interest in our article1 and for their thoughts on the 
interpretation of our findings.  The authors highlight in their letter the relative knowledge gaps and 
need for additional studies to improve our understanding of the temporal changes in the fibrinolytic 
system following trauma with which we fully concur.  However, we challenge their interpretation and 
conclusions regarding the potential role of S100A10 and its utility as a future therapeutic target. 
 
Viscoelastic hemostatic assays (VHAs) are a relatively blunt tool for the detection of fibrinolysis and it 
is unclear precisely what VHA-hypofibrinolysis represents in the fibrinolytic system in-vivo.  We and 
others2 have identified trauma patients with low-VHA fibrinolysis to be a heterogeneous subgroup, in 
terms of injury characteristics, levels of fibrinolysis biomarkers and clinical outcomes, with some 
suggesting it may represent a protective or adaptive response3.  Moore et al. have questioned our 
proposal that tissue-bound S100A10 fibrinolysis receptor is a mechanistic candidate for 
hyperfibrinolysis whilst simultaneously lowering VHA fibrinolysis ex-vivo.  We concur that further 
research is required to explore the role of S100A10 in-vivo and in particular its role at the endothelial 
surface - an area of investigation which has been hampered by the inherent limitations of currently 
available VHA assays.  However, the known pathophysiology of Acute Promyelocytic Leukemia 
provides biological plausibility for our assertion of severe hemorrhagic complications due to 
excessive fibrinolysis characterized by normal levels of tissue plasminogen activator (tPA) but high 
surface expression of S100A104.  
 
We would not expect S100A10 spiking of healthy blood to increase Plasmin-α2-antiplasmin complex 
(PAP) or D dimers (DD) since the detection of fibrinolysis with ROTEM requires plasmin production 
ex-vivo and S100A10 is known to lyse plasmin thus in the absence of tPA e.g. in healthy subjects or 
trauma patients with low maximum lysis (ML) and high DD, no plasmin can be generated. A number 
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of studies have identified S100A10 as a key plasminogen receptor and a major regulator of cellular 
plasmin generation.5 The accumulation of fibrin in the tissues of the S100A10-null mouse as well as 
the reduction in fibrinolysis further highlight the importance of S100A10 in fibrinolysis.6  The 
carboxyl-terminal lysine of the plasminogen receptor, S100A10 is not the sole lysine residue involved 
in acceleration of tissue plasminogen-dependent plasminogen activation7 although it is unknown if 
tranexamic acid (TXA) in the context of TBI and S100A10 mediated lysis or a specific S100A10 
inhibitor is most effective in reversing fibrinolysis. 
 
In focusing solely on hyperfibrinolysis leading to early death from uncontrolled hemorrhage, we 
believe this misses the wider implications of our study, particularly in the setting of traumatic brain 
injury (TBI).  Central in our findings was that the low ML high DD cohort represents polytrauma 
patients with a preponderance of severe TBI.  We were not able to examine cause of death but in the 
ML low DD high (raised S100A10) patients, the Kalpan-Meier curves are suggestive of patients dying 
of severe TBI (24-72 hours) rather than acutely from hemorrhage.  The rate of massive transfusion in 
this subgroup is plausible given the significant bleeding that is known to occur with severe TBI 
requiring operative intervention. Progression of intracranial hemorrhage following TBI is recognized 
as a major contributor to secondary brain injury and poorer outcomes, with fibrinolytic activation 
identified as a major contributor to hemorrhage progression8.   
 
S100A10 is in essence a receptor which promotes fibrinolysis and is expressed widely within the 
brain.  Current evidence suggests that the antifibrinolytic TXA can reduce intracranial hemorrhage 
progression in TBI9 and when administered empirically in the prehospital phase to patients with 
suspected TBI improves survival without increasing the rate of thromboembolic events.10 Pending the 
results of the CRASH-3 trial due to be released shortly, these results suggest a beneficial role for 
4 
 
targeted TXA administration in patients with a TBI, to reduce non-hemorrhage related deaths and to 
reduce the burden of morbidity associated with major bleeding and TBI. 
 
The precise mechanism for TBI associated fibrinolysis and relative role of S100A10 with respect to 
other mediators of fibrinolysis is at present not clear.  We propose S100A10 as one possible 
explanation given its patterns of tissue expression in the brain, in-vitro effects and correlation with 
elevated D-dimers.  Defining VHA-hypofibrinolysis at admission is problematic and temporal trends 
are likely more important in understanding fibrinolysis and associated outcomes as suggested by Dr 
Moore and others in their recent review on fibrinolysis shutdown in trauma.11 Detailed serial 
biomarker studies are clearly required to ascertain the significance of the many plasminogen 
receptors that are currently known and key pathways which both drive and inhibit fibrinolysis.      In 
addition delineation of local versus systemic effects of S100A10 and other mediators of lysis both in 
TBI and non-TBI polytrauma are required. These areas remain the subject of ongoing investigation 
both by our research team and others. The imminent publication of the CRASH-3 trial is sure to spark 
a further period of welcome and intense scientific debate, whether it demonstrates a positive or 
negative effect of anti-fibrinolytic therapy in TBI. 
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